Developer docs
API playgroundTry for free, no card

Search company profiles

BugSeq Bioinformatics

Full company profile

uuid000clkt

Namestring
BugSeq Bioinformatics
Legal namestring
BugSeq Bioinformatics Inc.
Websiteurl
bugseq.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

BugSeq Bioinformatics Inc. is a Vancouver-based, US-incorporated cloud bioinformatics company founded in 2020 that operates a fully automated platform for clinical and public health microbiology laboratories. The platform ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, eliminating the need for in-house bioinformatics infrastructure. The company's core technical differentiator is its curated reference database, which reports less than 0.0001% taxonomic misannotation and sequence contamination versus standard RefSeq-based pipelines, and its pathogen-specific pipeline library covering more than 20,000 bacteria, 10,000 viruses, 20,000 fungi, and 1,000 parasites.

The product portfolio consists of a single BugSeq Platform with eight integrated analysis modules, four clinical applications (clinical metagenomics, hospital-acquired infections, 16S/ITS, viral analysis), and pathogen-specific pipelines organized by organism kingdom. BugSeq distributes via a hybrid product-led and enterprise sales motion: a free 10-sample self-serve trial converts users into one of three annual subscription tiers (Core up to 1,000 samples/year, Advanced up to 3,000 with SSO and validation tooling, and Premier up to 7,000 with API integration for regulated diagnostics), while enterprise field sales target clinical labs, public health agencies, and defense organizations through quote-based pricing. The company reports being trusted by hundreds of labs and supports multiple peer-reviewed publications validating its accuracy.

Revenue mechanics are SaaS subscription-based with annual billing, supplemented by consortium and grant funding. BugSeq joined the RANGER consortium in February 2025 (led by Ginkgo Bioworks with Jumpcode Genomics, Planet Innovation, TGen, and funded by the European Commission's HERA budget) to develop an end-to-end rapid metagenomic diagnostic device eligible for up to €24 million over four years, with clinical validation at UZ Leuven, Karolinska University Hospital, and Tartu University Hospital as part of a path to EU IVDR certification. CEO Sam Chorlton leads the company, which currently operates with 1-10 employees.

Short descriptiontext

BugSeq Bioinformatics is a cloud-based automated bioinformatics platform that processes raw sequencing data from Illumina, Nanopore, and PacBio instruments for clinical microbiology, public health, and defense laboratories, delivering pathogen identification and antimicrobial resistance prediction within hours.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
metagenomic sequencing analysis, clinical bioinformatics platform, antimicrobial resistance prediction, pathogen identification software, outbreak surveillance genomics
Industry1 code
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Clinical Bioinformatics Software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Subscription-based SaaS Platform
TypeSubscription Recurring
Description

BugSeq operates on a subscription SaaS model with tiered pricing (Core, Advanced, Premier) based on sample volume and feature access. Pricing scales with annual sample volume from 1000 samples/year (Core) to 7000 samples/year (Premier), with additional features like data retention, SSO, pipeline versioning, and API integration at higher tiers.

bugseq.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details3 tiers
1Core plan - Foundational tools for high-impact research and pilot studies
ModelSubscriptionBilling cadenceAnnual
Notes

Up to 1000 samples per year, any type of analysis (metagenomics, 16S, isolates), 24/7 support, 1 year data retention, 2 hour turnaround time, up to 3 users

bugseq.com
2Advanced plan - Routine volume, collaboration and compliance
ModelSubscriptionBilling cadenceAnnual
Notes

Up to 3000 samples per year, 6 year data retention, SSO support, pipeline versioning and validation tooling, unlimited users

bugseq.com
3Premier plan - Gold standard for regulated molecular diagnostics and IVD
ModelSubscriptionBilling cadenceAnnual
Notes

Up to 7000 samples per year, API integration support

bugseq.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

BugSeq operates a fully automated, cloud-based bioinformatics platform for microbiology labs that ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces actionable taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, without requiring dedicated bioinformatics infrastructure. It is sold as a tiered annual SaaS subscription (Core, Advanced, Premier) scaled by annual sample volume and regulatory feature requirements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Taxonomic misannotation reduced to <0.0001% vs 1% in RefSeq
+3 more records
Product overview1 text field

BugSeq is a fully automated cloud-based bioinformatics platform offering end-to-end pathogen analysis for microbiology labs. The platform processes raw sequencing data from Illumina, Nanopore, and PacBio instruments, providing taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification. The product portfolio consists of a core platform with multiple integrated analysis modules (Taxonomic Classification, Antimicrobial Resistance Analysis, Outbreak Analysis, Plasmid Detection, Quality Control, Subtyping, Pathogen Identification, and Curated Database), pathogen-specific pipelines for bacteria (20,000+), viruses (10,000+), fungi (20,000+), and parasites (1,000+), and four clinical applications (Clinical Metagenomics, Hospital Acquired Infections, 16S/ITS Analysis, and Viral Analysis). Pricing is offered in three tiers: Core (up to 1000 samples/year), Advanced (up to 3000 samples/year with SSO and validation tooling), and Premier (up to 7000 samples/year with API integration for regulated diagnostics/IVD).

Product and service1 record
1BugSeq Platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

BugSeq participates in the RANGER (RApid Next Generation Sequencing for Effective Medical Response) consortium led by Ginkgo Bioworks to develop a rapid, metagenomic next-generation sequencing (mNGS) solution enabling same-day diagnostics for respiratory viruses in hospitals. Consortium partners eligible for up to €24 million in funding over four years through European Commission HERA budget.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

Jumpcode Genomics is a consortium partner in the RANGER project providing CRISPR-based technology for the Cipher system. Their expertise complements BugSeq's bioinformatics platform in the integrated diagnostic solution.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

Planet Innovation leverages its product development and manufacturing capabilities to develop the Cipher benchtop system. Their expertise in world-class platform development complements BugSeq's bioinformatics analysis capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-20
Description

TGen is a consortium partner contributing to clinical validation of the rapid metagenomic diagnostic solution developed through the RANGER project.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-02-20
Description

BugSeq partners with Oxford Nanopore for joint webinars on real-time infectious disease outbreak investigations using nanopore sequencing and BugSeq analysis. BugSeq's platform is optimized for Nanopore long-read sequencing data.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Open-source metagenomics analysis platform developed at the Chan Zuckerberg Biohub for pathogen detection from sequencing data. Comparable in core functionality (taxonomic classification, AMR, outbreak tracking) and partially in target users (public health and research labs), but offered free versus BugSeq's subscription model.

TypeBroad incumbent
Description

Global leader in in vitro diagnostics for clinical microbiology, including molecular diagnostics and antimicrobial susceptibility testing. Comparable as a broader incumbent whose installed base in clinical microbiology labs is the customer ecosystem BugSeq is targeting with sequencing-based analysis.

TypeBroad incumbent
Description

Dominant sequencing vendor offering DRAGEN bioinformatics for secondary and tertiary analysis of sequencing data, including metagenomics. Comparable as the most entrenched incumbent that bundles analytics with its instruments and competes for the same clinical microbiology and public health budgets.

TypeOthers
Description

Synthetic biology platform and R&D services company that leads the RANGER consortium in which BugSeq participates. Comparable because Ginkgo is both a partner and adjacent competitor with growing capabilities in pathogen genomics, biosecurity and large-scale metagenomic programs.

TypeOthers
Description

Cloud genomics data platform offering infrastructure, pipelines and analysis environments for sequencing data. Comparable as enabling infrastructure that competes for clinical bioinformatics workloads and could host alternative metagenomics pipelines to BugSeq.

TypeDirect peer
Description

Cloud-based microbial genomics platform offering taxonomic classification and AMR analysis for sequencing data. Directly comparable as a SaaS bioinformatics platform focused on microbial identification and AMR, serving both clinical and food/agriculture testing labs.

TypeDirect peer
Description

Clinical infectious disease diagnostics company using sequencing (cell-free DNA) to identify pathogens from blood samples. Comparable as a clinical metagenomics player pursuing hospital adoption of sequencing-based pathogen detection, with overlapping regulatory and clinical validation challenges.

TypeDirect peer
Description

Commercial microbial identification and AMR platform built on curated databases and metagenomic analysis. Directly comparable in target customers (clinical and food safety labs), core function (pathogen ID + AMR) and business model (subscription bioinformatics for sequencing data).

TypeDirect peer
Description

Sequencing platform vendor with EPI2ME, its native bioinformatics suite for metagenomic and pathogen analysis on Nanopore data. Highly comparable because BugSeq's platform is optimized for and partnered with Nanopore, and EPI2ME represents the most direct competitive alternative for Nanopore customers.

TypeBroad incumbent
Description

Broad life sciences tools company with CLC Genomics Workbench and QIAseq bioinformatics solutions used in microbial genomics and clinical research. Comparable because it offers an established, regulated bioinformatics platform that competes for the same clinical and public health laboratory customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BugSeq Bioinformatics

Clinical Bioinformatics Softwarebugseq.com

BugSeq Bioinformatics is a cloud-based automated bioinformatics platform that processes raw sequencing data from Illumina, Nanopore, and PacBio instruments for clinical microbiology, public health, and defense laboratories, delivering pathogen identification and antimicrobial resistance prediction within hours.

What BugSeq Bioinformatics does

BugSeq Bioinformatics Inc. is a Vancouver-based, US-incorporated cloud bioinformatics company founded in 2020 that operates a fully automated platform for clinical and public health microbiology laboratories. The platform ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, eliminating the need for in-house bioinformatics infrastructure. The company's core technical differentiator is its curated reference database, which reports less than 0.0001% taxonomic misannotation and sequence contamination versus standard RefSeq-based pipelines, and its pathogen-specific pipeline library covering more than 20,000 bacteria, 10,000 viruses, 20,000 fungi, and 1,000 parasites.

The product portfolio consists of a single BugSeq Platform with eight integrated analysis modules, four clinical applications (clinical metagenomics, hospital-acquired infections, 16S/ITS, viral analysis), and pathogen-specific pipelines organized by organism kingdom. BugSeq distributes via a hybrid product-led and enterprise sales motion: a free 10-sample self-serve trial converts users into one of three annual subscription tiers (Core up to 1,000 samples/year, Advanced up to 3,000 with SSO and validation tooling, and Premier up to 7,000 with API integration for regulated diagnostics), while enterprise field sales target clinical labs, public health agencies, and defense organizations through quote-based pricing. The company reports being trusted by hundreds of labs and supports multiple peer-reviewed publications validating its accuracy.

Revenue mechanics are SaaS subscription-based with annual billing, supplemented by consortium and grant funding. BugSeq joined the RANGER consortium in February 2025 (led by Ginkgo Bioworks with Jumpcode Genomics, Planet Innovation, TGen, and funded by the European Commission's HERA budget) to develop an end-to-end rapid metagenomic diagnostic device eligible for up to €24 million over four years, with clinical validation at UZ Leuven, Karolinska University Hospital, and Tartu University Hospital as part of a path to EU IVDR certification. CEO Sam Chorlton leads the company, which currently operates with 1-10 employees.

BugSeq Bioinformatics firmographics

Firmographics
Name
BugSeq Bioinformatics
Legal name
BugSeq Bioinformatics Inc.
Website
https://bugseq.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
BugSeq Bioinformatics is a cloud-based automated bioinformatics platform that processes raw sequencing data from Illumina, Nanopore, and PacBio instruments for clinical microbiology, public health, and defense laboratories, delivering pathogen identification and antimicrobial resistance prediction within hours.
Ownership category
akta.pro rank

Where BugSeq Bioinformatics is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Markets served

BugSeq Bioinformatics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Subscription-based SaaS Platform: BugSeq operates on a subscription SaaS model with tiered pricing (Core, Advanced, Premier) based on sample volume and feature access. Pricing scales with annual sample volume from 1000 samples/year (Core) to 7000 samples/year (Premier), with additional features like data retention, SSO, pipeline versioning, and API integration at higher tiers.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualCore plan - Foundational tools for high-impact research and pilot studies
SubscriptionAnnualAdvanced plan - Routine volume, collaboration and compliance
SubscriptionAnnualPremier plan - Gold standard for regulated molecular diagnostics and IVD

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

BugSeq Bioinformatics product offering

Product offering

Core offering

BugSeq operates a fully automated, cloud-based bioinformatics platform for microbiology labs that ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces actionable taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, without requiring dedicated bioinformatics infrastructure. It is sold as a tiered annual SaaS subscription (Core, Advanced, Premier) scaled by annual sample volume and regulatory feature requirements.

Product overview

BugSeq is a fully automated cloud-based bioinformatics platform offering end-to-end pathogen analysis for microbiology labs. The platform processes raw sequencing data from Illumina, Nanopore, and PacBio instruments, providing taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification. The product portfolio consists of a core platform with multiple integrated analysis modules (Taxonomic Classification, Antimicrobial Resistance Analysis, Outbreak Analysis, Plasmid Detection, Quality Control, Subtyping, Pathogen Identification, and Curated Database), pathogen-specific pipelines for bacteria (20,000+), viruses (10,000+), fungi (20,000+), and parasites (1,000+), and four clinical applications (Clinical Metagenomics, Hospital Acquired Infections, 16S/ITS Analysis, and Viral Analysis). Pricing is offered in three tiers: Core (up to 1000 samples/year), Advanced (up to 3000 samples/year with SSO and validation tooling), and Premier (up to 7000 samples/year with API integration for regulated diagnostics/IVD).

Differentiator

Problem solved

Functional benefit

Products and services

  • BugSeq Platform

Quantifiable outcome

  • Taxonomic misannotation reduced to <0.0001% vs 1% in RefSeq
  • +3 more outcomes

Companies that use BugSeq Bioinformatics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

BugSeq Bioinformatics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature9 records

BugSeq Bioinformatics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Ginkgo BioworkscoreStrategic or Co-development Partner · 20 February 2025BugSeq participates in the RANGER (RApid Next Generation Sequencing for Effective Medical Response) consortium led by Ginkgo Bioworks to develop a rapid, metagenomic next-generation sequencing (mNGS) solution enabling same-day diagnostics for respiratory viruses in hospitals. Consortium partners eligible for up to €24 million in funding over four years through European Commission HERA budget.
  • Jumpcode GenomicscoreStrategic or Co-development Partner · 20 February 2025Jumpcode Genomics is a consortium partner in the RANGER project providing CRISPR-based technology for the Cipher system. Their expertise complements BugSeq's bioinformatics platform in the integrated diagnostic solution.
  • Planet InnovationcoreStrategic or Co-development Partner · 20 February 2025Planet Innovation leverages its product development and manufacturing capabilities to develop the Cipher benchtop system. Their expertise in world-class platform development complements BugSeq's bioinformatics analysis capabilities.
  • TGen (Translational Genomics Research Institute)coreStrategic or Co-development Partner · 20 February 2025TGen is a consortium partner contributing to clinical validation of the rapid metagenomic diagnostic solution developed through the RANGER project.
  • Oxford Nanopore TechnologiescoreTechnology or Integration · 20 February 2025BugSeq partners with Oxford Nanopore for joint webinars on real-time infectious disease outbreak investigations using nanopore sequencing and BugSeq analysis. BugSeq's platform is optimized for Nanopore long-read sequencing data.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

BugSeq Bioinformatics competitors and assessment

Company assessment

Emerging players

  • Chan Zuckerberg Biohub (IDseq): Open-source metagenomics analysis platform developed at the Chan Zuckerberg Biohub for pathogen detection from sequencing data. Comparable in core functionality (taxonomic classification, AMR, outbreak tracking) and partially in target users (public health and research labs), but offered free versus BugSeq's subscription model.

Broad incumbents

  • bioMérieux: Global leader in in vitro diagnostics for clinical microbiology, including molecular diagnostics and antimicrobial susceptibility testing. Comparable as a broader incumbent whose installed base in clinical microbiology labs is the customer ecosystem BugSeq is targeting with sequencing-based analysis.
  • Illumina: Dominant sequencing vendor offering DRAGEN bioinformatics for secondary and tertiary analysis of sequencing data, including metagenomics. Comparable as the most entrenched incumbent that bundles analytics with its instruments and competes for the same clinical microbiology and public health budgets.
  • QIAGEN: Broad life sciences tools company with CLC Genomics Workbench and QIAseq bioinformatics solutions used in microbial genomics and clinical research. Comparable because it offers an established, regulated bioinformatics platform that competes for the same clinical and public health laboratory customers.

Others

  • Ginkgo Bioworks: Synthetic biology platform and R&D services company that leads the RANGER consortium in which BugSeq participates. Comparable because Ginkgo is both a partner and adjacent competitor with growing capabilities in pathogen genomics, biosecurity and large-scale metagenomic programs.
  • DNAnexus: Cloud genomics data platform offering infrastructure, pipelines and analysis environments for sequencing data. Comparable as enabling infrastructure that competes for clinical bioinformatics workloads and could host alternative metagenomics pipelines to BugSeq.

Direct peers

  • One Codex: Cloud-based microbial genomics platform offering taxonomic classification and AMR analysis for sequencing data. Directly comparable as a SaaS bioinformatics platform focused on microbial identification and AMR, serving both clinical and food/agriculture testing labs.
  • Karius: Clinical infectious disease diagnostics company using sequencing (cell-free DNA) to identify pathogens from blood samples. Comparable as a clinical metagenomics player pursuing hospital adoption of sequencing-based pathogen detection, with overlapping regulatory and clinical validation challenges.
  • CosmosID: Commercial microbial identification and AMR platform built on curated databases and metagenomic analysis. Directly comparable in target customers (clinical and food safety labs), core function (pathogen ID + AMR) and business model (subscription bioinformatics for sequencing data).
  • Oxford Nanopore Technologies: Sequencing platform vendor with EPI2ME, its native bioinformatics suite for metagenomic and pathogen analysis on Nanopore data. Highly comparable because BugSeq's platform is optimized for and partnered with Nanopore, and EPI2ME represents the most direct competitive alternative for Nanopore customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

BugSeq Bioinformatics social profiles

Digital presence

BugSeq Bioinformatics compliance and trust

Trust signal

Compliance2 records

BugSeq Bioinformatics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BugSeq Bioinformatics leadership team

Management profile

Number of profiles

Profiles1 record

BugSeq Bioinformatics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BugSeq Bioinformatics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BugSeq Bioinformatics

What does BugSeq Bioinformatics do?

BugSeq operates a fully automated, cloud-based bioinformatics platform for microbiology labs that ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces actionable taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, without requiring dedicated bioinformatics infrastructure. It is sold as a tiered annual SaaS subscription (Core, Advanced, Premier) scaled by annual sample volume and regulatory feature requirements.

Is BugSeq Bioinformatics a public or private company?

BugSeq Bioinformatics is a private company. It is classified as unknown and is currently operating.

When was BugSeq Bioinformatics founded?

BugSeq Bioinformatics was founded in 2020. It employs 1 to 10 people.

Where is BugSeq Bioinformatics based?

BugSeq Bioinformatics is headquartered in Vancouver, Canada, in the North America region.

How does BugSeq Bioinformatics make money?

One revenue line is on record: subscription-based SaaS Platform.

Who are BugSeq Bioinformatics's main competitors?

Chan Zuckerberg Biohub (IDseq) is listed as an emerging player. Broad incumbents are bioMérieux, Illumina and QIAGEN. Others are Ginkgo Bioworks and DNAnexus. Direct peers are One Codex, Karius, CosmosID and Oxford Nanopore Technologies.

Does BugSeq Bioinformatics have an API?

Yes. BugSeq offers API integration support for Premier plan customers (up to 7000 samples per-year). Documentation is available at https://docs.bugseq.com. Additional details on API availability, endpoints, authentication methods, and rate limits are not publicly specified on the website. Developer documentation is at docs.bugseq.com.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals